And when the sole therapy available to end-stage prostate cancer patients is Taxotere (docetaxel)—which extends survival by only two-and-a-half months and is so toxic it kills 300 patients ...

It found that one in 20 men with advanced prostate cancer responded to the ... "But our study shows that a small proportion of men with end-stage cancer do respond, and crucially that some of ...

Findings published in the Journal of Clinical Oncology show that one in 20 men with end-stage prostate cancer responded to Keytruda, but although the number who benefited was small, these patients ...